Els Everaert
9 Papers
18 Citations
Els Everaert is an academic researcher. The author has contributed to research in topics: Prostate cancer & Abiraterone acetate. The author has an hindex of 6, co-authored 9 publications.
Chat about Author
Papers
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.
Markus Mayrhofer,Bram De Laere,Bram De Laere,Tom Whitington,Peter Van Oyen,Christophe Ghysel,Jozef Ampe,Piet Ost,Wim Demey,Lucien Hoekx,Dirk Schrijvers,Barbara Brouwers,Willem Lybaert,Els Everaert,Daan De Maeseneer,Michiel Strijbos,Alain Bols,Karen Fransis,Steffi Oeyen,Peter A. van Dam,Gert Van den Eynden,Annemie Rutten,Markus Aly,Tobias Nordström,Steven Van Laere,Mattias Rantalainen,Prabhakar Rajan,Lars Egevad,Anders Ullén,Jeffrey Yachnin,Luc Dirix,Henrik Grönberg,Johan Lindberg +32 more
TL;DR: ctDNA profiles appear to mirror the genomic landscape of metastatic prostate cancer tissue and may cost-efficiently provide somatic information in clinical trials designed to identify predictive biomarkers, however, intronic sequencing of the interrogated tumor suppressors challenges the ubiquitous focus on coding regions.
129
Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
Martin Boegemann,S. Khaksar,Guillaume Bera,Alison Birtle,Catherine Dopchie,Louis-Marie Dourthe,Els Everaert,Martin Hatzinger,Dirko Hercher,Werner Hilgers,Geoffrey Matus,Laura Garcia Alvarez,Laurent Antoni,M Lukac,Geneviève Pissart,Paul Robinson,Tony Elliott +16 more
TL;DR: Treatment effectiveness of AAP in the real-world is maintained despite patients having poorer clinical features at initiation than those observed in the COU-AA-302 trial population, and patients with longer duration of response to ADT presented longer TTF and longer time to progression.
Circulating tumor cells and survival in abiraterone‐ and enzalutamide‐treated patients with castration‐resistant prostate cancer
Bram De Laere,Steffi Oeyen,Peter Van Oyen,Christophe Ghysel,Jozef Ampe,Piet Ost,Wim Demey,Lucien Hoekx,Dirk Schrijvers,Barbara Brouwers,Willem Lybaert,Els Everaert,Piet Van Kerckhove,Daan De Maeseneer,Michiel Strijbos,Alain Bols,Karen Fransis,Nick Beije,Inge de Kruijff,Valerie van Dam,Anja Brouwer,Peter A. van Dam,Gert Van den Eynden,Annemie Rutten,Stefan Sleijfer,Jean Vandebroek,Steven Van Laere,Luc Dirix +27 more
TL;DR: The outcome to treatment administered to patients with metastatic castration‐resistant prostate cancer (mCRPC) greatly differs between individuals, underlining the need for biomarkers guiding treatment decision making.
Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program
Charles Van Praet,Sylvie Rottey,Fransien Van Hende,Gino Pelgrims,Wim Demey,Filip Van Aelst,W. Wynendaele,Thierry Gil,Peter Schatteman,Bertrand Filleul,Denis Schallier,Jean Pascal Machiels,Dirk Schrijvers,Els Everaert,Lionel D'Hondt,Patrick Werbrouck,Joanna Vermeij,Jeroen Mebis,Marylene Clausse,Marika Rasschaert,Joanna Van Erps,Jolanda Verheezen,Jan Van Haverbeke,Jean-Charles Goeminne,Nicolaas Lumen +24 more
TL;DR: These real-world data on post-docetaxel AA efficacy are in line with the COU-AA-301 trial, and incidence of severe anemia and hypokalemia is up to 50% higher than reported in previous studies.
Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?
Charles Van Praet,Sylvie Rottey,Fransien Van Hende,Gino Pelgrims,Wim Demey,Filip Van Aelst,W. Wynendaele,Thierry Gil,Peter Schatteman,Bertrand Filleul,Denis Schallier,Jean Pascal Machiels,Dirk Schrijvers,Els Everaert,Lionel D'Hondt,Patrick Werbrouck,Joanna Vermeij,Jeroen Mebis,Marylene Clausse,Marika Rasschaert,Joanna Van Erps,Jolanda Verheezen,Jan Van Haverbeke,Jean-Charles Goeminne,Nicolaas Lumen +24 more
TL;DR: In this article, a multivariate model was constructed, based on 220 patients, incorporating five independent risk factors for decreased overall survival at the time of AA initiation: hemoglobin 10 metastases (HR 1.80), ECOG performance status, radiographic progression, and time since diagnosis.
10